US Proposal Could Halve Biocon’s Biosimilar Development Costs
N Shorts
US Proposal Could Halve Biocon's Biosimilar Development Costs
India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
Technically enhanced content presented under fair use in public-interest journalism.
Listen:
